Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 10Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Pancreatic Neoplasms 5Neoplastic Cells, Circulating 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm, Residual 3Disease 3Nevi and Melanomas 2Neuroendocrine Tumors 2Neoplasms 2Nasopharyngeal Carcinoma 2NSCLC 2Melanoma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Smoking 1

Interventions

Imatinib Mesylate 71Sunitinib 31regorafenib 17nilotinib 15ripretinib 13avapritinib 7Laparoscopy 5Ipilimumab 5Dasatinib 5spartalizumab 4CTLA-4 Antigen 4Blood Specimen Collection 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Oxaliplatin 3Observation 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Biopsy 3Bevacizumab 3trametinib 2tanespimycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Liquid Biopsy × Clear all
NCT05408897 2022-09-21

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Peking University People's Hospital

Recruiting
45 enrolled
GastrointestinalSarcoma

Neoplasm, Residual, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡